ocugen
present
oppenheimer
fall
healthcare
life
sciences
medtech
summit
malvern
globe
newswire
ocugen
nasdaq
ocgn
biopharmaceutical
company
focused
discovering
developing
commercializing
transformative
therapies
cure
blindness
diseases
today
announced
present
oppenheimer
fall
healthcare
life
sciences
medtech
summit
september
shankar
musunuri
chairman
ceo
present
virtually
provide
update
development
ocugen
breakthrough
modifier
gene
therapy
platform
well
novel
biologic
product
candidate
highlight
ocugen
lead
product
candidate
potential
treat
many
forms
retinitis
pigmentosa
received
fourth
fda
orphan
drug
designation
musunuri
share
ocugen
recent
accomplishments
upcoming
planned
near
milestones
presentation
details
conference
oppenheimer
fall
healthcare
life
sciences
medtech
summit
format
company
presentation
date
monday
september
time
pm
eastern
time
webcast
link
https
webcast
ocgn
oppenheimer
fall
healthcare
life
sciences
medtech
summit
take
place
virtually
september
ocugen
ocugen
biopharmaceutical
company
focused
discovering
developing
commercializing
transformative
therapies
cure
blindness
diseases
breakthrough
modifier
gene
therapy
platform
potential
treat
multiple
retinal
diseases
one
drug
one
many
novel
biologic
product
candidate
aims
offer
better
therapy
patients
underserved
diseases
wet
macular
degeneration
diabetic
macular
edema
diabetic
retinopathy
information
please
visit
cautionary
note
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
subject
risks
uncertainties
may
cases
use
terms
predicts
believes
potential
proposed
continue
estimates
anticipates
expects
plans
intends
may
could
might
words
convey
uncertainty
future
events
outcomes
identify
statements
statements
subject
numerous
important
factors
risks
uncertainties
may
cause
actual
events
results
differ
materially
current
expectations
risks
uncertainties
fully
described
periodic
filings
securities
exchange
commission
sec
including
risk
factors
described
section
entitled
risk
factors
quarterly
annual
reports
file
sec
statements
make
press
release
speak
date
press
release
except
required
law
assume
obligation
update
statements
contained
press
release
whether
result
new
information
future
events
otherwise
date
press
release
